Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib vs Standard Therapy in Advanced or Metastatic RET Fusion-Positive NSCLC
NCT04194944Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 26
01
Overview
A Phase 3 trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Feb 2020; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04194944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194944.